Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Liabilities and Shareholders Equity: 2013-2025

Historic Liabilities and Shareholders Equity for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $410.9 million.

  • Ocular Therapeutix's Liabilities and Shareholders Equity fell 16.21% to $410.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 4.03%. This contributed to the annual value of $457.9 million for FY2024, which is 81.68% up from last year.
  • According to the latest figures from Q3 2025, Ocular Therapeutix's Liabilities and Shareholders Equity is $410.9 million, which was down 8.96% from $451.3 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Liabilities and Shareholders Equity registered a high of $538.9 million during Q1 2024, and its lowest value of $122.6 million during Q2 2023.
  • In the last 3 years, Ocular Therapeutix's Liabilities and Shareholders Equity had a median value of $410.9 million in 2025 and averaged $358.0 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Liabilities and Shareholders Equity plummeted by 31.47% in 2023, and later spiked by 321.92% in 2024.
  • Ocular Therapeutix's Liabilities and Shareholders Equity (Quarterly) stood at $204.9 million in 2021, then dropped by 27.14% to $149.3 million in 2022, then surged by 68.84% to $252.1 million in 2023, then spiked by 81.68% to $457.9 million in 2024, then dropped by 16.21% to $410.9 million in 2025.
  • Its Liabilities and Shareholders Equity was $410.9 million in Q3 2025, compared to $451.3 million in Q2 2025 and $405.9 million in Q1 2025.